Four Independent Scientific Abstracts at the American Academy of Dental Sleep Medicine Annual Meeting Feature ProSomnus Intraoral Medical Devices
May 09, 2024 18:30 ET
|
ProSomnus Sleep Technologies, Inc.
Four Independent Scientific Abstracts at the American Academy of Dental Sleep Medicine Annual Meeting Feature ProSomnus Intraoral Medical Devices
Sensus Healthcare Reports First Quarter 2024 Financial Results With Revenues up More than Three-fold
May 09, 2024 16:05 ET
|
Sensus Healthcare, Inc.
Revenues of $10.7 million, compared with $3.4 million in the prior-year quarter; Adjusted EBITDA (a non-GAAP measure) of $3.0 million, compared with negative $2.7 million in the prior-year...
Collegium Reports First Quarter 2024 Financial Results
May 09, 2024 16:02 ET
|
Collegium Pharmaceutical, Inc.
– Generated Q1’24 Net Revenue of $144.9 Million – – Delivered Q1’24 Record Belbuca® Revenue of $50.7 Million; Total Prescriptions Up 4.2% Year-over-Year – – Achieved Q1’24 GAAP Net...
Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
May 09, 2024 16:02 ET
|
Allakos Inc.
SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and...
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
May 09, 2024 16:01 ET
|
Dianthus Therapeutics, Inc.
Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing, with top-line results anticipated in 2H’25 Building a neuromuscular franchise with DNTH103; Phase 2 trial in Multifocal Motor...
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024 16:01 ET
|
Xenon Pharmaceuticals Inc.
Phase 3 epilepsy program continues to progress with anticipated completion of patient enrollment in X-TOLE2 in late 2024 to early 2025 Successful “end-of-Phase 2” interactions with FDA in MDD; Phase...
Psoriasis Vulgaris Clinical Trial Pipeline Analysis Demonstrates 50+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
May 09, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, May 09, 2024 (GLOBE NEWSWIRE) -- Psoriasis Vulgaris Clinical Trial Pipeline Analysis Demonstrates 50+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm,...
MeiraGTx Reports First Quarter 2024 Financial and Operational Results
May 09, 2024 08:00 ET
|
MeiraGTx
- Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX) presented in an oral session at the American Academy of Oral Medicine 2024 annual meeting (AAOM) April 17-20, 2024 -...
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
May 07, 2024 08:00 ET
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and EMA on the regulatory path for the Phase 3...
Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 06, 2024 16:01 ET
|
Celldex Therapeutics, Inc.
- Phase 3 CSU studies expected to initiate in summer 2024 -- Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 --...